THE
      SECURITIES REPRESENTED BY THIS OPTION ARE NOT TRANSFERABLE WITHOUT THE EXPRESS
      WRITTEN CONSENT OF ZIOPHARM, INC. (THE "COMPANY") AND HAVE NOT BEEN REGISTERED
      UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES
      LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED OR
      OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT
      WITH
      RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN EXEMPTION FROM SUCH ACT. ANY
      SUCH
      TRANSFER MAY ALSO BE SUBJECT TO APPLICABLE STATE SECURITIES
      LAWS.

    


    ZIOPHARM,
      INC.

     

    Option
      for the Purchase of Shares of 

    Common
      Stock

    


    October
      15, 2004

    


     

    
      	No. DT-1	
              55,125
                Shares

            


    

    


    FOR
      VALUE
      RECEIVED, ZIOPHARM, INC., a Delaware corporation (the “Company”),
      hereby certifies that DEKK-Tec, Inc. or its registered assigns (the
“Holder”)
      is
      entitled to purchase from the Company, subject to the provisions of this Option,
      at any time following the applicable Vesting Date (as defined below) and prior
      to 5:00 P.M. Eastern Standard Time on the date that is five years from such
      Vesting Date (the “Termination
      Date”),
      Fifty-Five Thousand One Hundred Twenty-five (55,125) fully paid and
      non-assessable shares of the Common Stock, $.001 par value, of the Company
      (“Common
      Stock”)
      at an
      initial per share exercise price equal to $0.01 (the “Per
      Share Exercise Price”),
      or an
      aggregate exercise price of $551.25 (the “Aggregate
      Exercise Price”).
      The
      shares of Common Stock deliverable upon such exercise are sometimes referred
      to
      in this Option as the “Option
      Shares.”
      

    


    This
      Option is being granted pursuant to the Section 4.1 of that certain License
      Agreement dated as of October 15, 2004 by and between the Company and DEKK-Tec,
      Inc. (the “License
      Agreement”).
      Capitalized terms not otherwise defined in this Option shall have the meanings
      ascribed to such terms in the License Agreement.

    


    1)    Exercise
      of Option.
      

    


    (a)   Following
      the Vesting Date and prior to the applicable Termination Date, this Option
      may
      be exercised in whole or in part, from time to time, by the Holder by
      presentation and surrender of this Option (with the subscription form attached
      to this Option duly executed) at the address set forth in Section 8 of this
      Option, together with payment, by certified or official bank check or wire
      transfer payable to the order of the Company, of the Aggregate Exercise Price
      or
      the proportionate part of such Aggregate Exercise Price if exercised in
      part.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b)   If
      this
      Option is exercised only in part, the Company shall, upon presentation of this
      Option upon such exercise, execute and deliver (with the certificate for the
      Option Shares purchased) a new Option evidencing the rights of the Holder of
      this Option to purchase the balance of the Option Shares purchasable under
      this
      Option upon the same terms and conditions as set forth in this Option. Upon
      proper exercise of this Option, the Company promptly shall deliver certificates
      for the Option Shares to the Holder duly legended as authorized by the
      subscription form. No fractional shares shall be issued upon exercise of this
      Option. Any fractional number of shares called for upon exercise of this Option
      shall be rounded down to the nearest whole share.

    


    2)    Vesting
      of Option.
      The
      Option shall vest and become exercisable for a percentage of the Option Shares
      as follows: (A) 12,500 Option Shares upon the Effective Date (October 15, 2004);
      (B) 12,500 Option Shares upon the
      dosing of the first patient in the first Phase III clinical trial of Licensed
      Product in the United States under a Company or Company sublicense sponsored
      IND;
      and (C)
      25,000 Option Shares upon the final approval by the FDA of the first NDA
      submitted by the Company or its sublicensee for a Licensed Product. The date
      that any Option Shares become exercisable shall be deemed the “Vesting
      Date”
with
      respect to such Option Shares. The Option shall remain exercisable for five
      years from the respective Vesting Dates for such portion of the Option Shares
      and shall thereafter become void. 

    


    3)    Adjustment.
      

     

    (a)   In
      case
      the Company shall (i) pay a dividend or make a distribution on its capital
      stock
      in shares of Common Stock or any other capital stock, (ii) subdivide its
      outstanding shares of Common Stock into a greater number of shares, (iii)
      combine its outstanding shares of Common Stock into a smaller number of shares
      or (iv) reclassify its Common Stock or effect a capital reorganization of the
      Company,
      or
      in
      case of the consolidation of the Company with or the merger of the Company
      with
      or into any other company or of the sale of the properties and assets of the
      Company as, or substantially as, an entirety to any other company,
      then the
      number and type of unexercised Option Shares subject to this Option shall be
      proportionately adjusted so that the Holder shall be entitled to receive the
      aggregate number and type of shares or other property that, if the unexercised
      Option Shares had been exercised in full immediately prior to such time, the
      Holder would have owned upon such exercise and been entitled to receive upon
      such dividend, subdivision, combination, reclassification or recapitalization.
      Whenever the number of shares issuable upon exercise of this Option is adjusted
      pursuant to this Section 3(a), the Per Share Exercise Price shall simultaneously
      be adjusted by multiplying the number of unexercised Option Shares issuable
      upon
      exercise of this Option by the Per Share Exercise Price in effect on the date
      thereof and dividing the product so obtained by the number of Option Shares
      issuable upon exercise of the Option immediately following the adjustments
      made
      in 3(a) above. Such adjustment shall be made successively whenever any event
      listed in this paragraph 3(a) shall occur. An adjustment made pursuant to this
      Subsection 3(a) shall become effective immediately after the record date in
      the
      case of a dividend or distribution and shall become effective immediately after
      the effective date in the case of a subdivision, combination or
      reclassification.

    


    
      
        
        

      

      
        -
          2
          -

        
          

        

      

      
        
        

      

    

     

    (b)   If,
      as a
      result of an adjustment made pursuant to this Section 3, the Holder shall become
      entitled to receive shares of two or more classes of capital stock or shares
      of
      Common Stock and other capital stock of the Company upon surrender of this
      Option , the Board of Directors (whose determination shall be conclusive and
      shall be described in a written notice to the Holder promptly after such
      adjustment) shall determine the allocation of the adjusted Per Share Exercise
      Price between or among shares or such classes of capital stock or shares of
      Common Stock and other capital stock.

    


    (c)   When
      any
      adjustment is required to be made in the number or kind of shares purchasable
      upon exercise of the Option, the Company shall promptly notify the Holder of
      such event and of the number of shares of securities or property thereafter
      purchasable upon exercise of the Option. 

    


    4)    Reservation
      of Option Shares; Fully Paid Shares; Taxes.
      The
      Company hereby undertakes until expiration of this Option to reserve for
      issuance or delivery upon exercise of this Option, such number of shares of
      the
      Common Stock as shall be required for issuance and/or delivery upon exercise
      of
      this Option in full, and agrees that all Option Shares so issued and/or
      delivered will be validly issued, fully-paid and non-assessable, and further
      agrees to pay all taxes and charges that may be imposed upon such issuance
      and/or delivery.

    


    5)    Limited
      Transferability.
      This
      Option may not be sold, transferred, assigned or hypothecated by the Holder
      except in compliance with the provisions of the Securities Act of 1933, as
      amended (the “Act”),
      and
      the applicable state securities or “blue sky” laws, and is so transferable only
      upon the books of the Company which the Company shall cause to be maintained
      for
      such purpose. The Company may treat the registered holder of this Option as
      such
      holder appears on the Company's books at any time as the holder for all
      purposes. All Options issued upon the transfer or assignment of this Option
      will
      be dated the same date as this Option, and all rights of the holder of such
      Option shall be identical to those of the Holder and upon such transfer or
      assignment, the Holder shall have no further rights under this
      Option.

    


    6)    Loss,
      etc., of Option.
      Upon
      receipt of evidence satisfactory to the Company of the loss, theft, destruction
      or mutilation of this Option, and of indemnity satisfactory to the Company,
      if
      lost, stolen or destroyed, and upon surrender and cancellation of this Option,
      if mutilated, the Company shall execute and deliver to the Holder a new Option
      of like date, tenor and denomination.

    


    7)    Status
      of Holder.
      This
      Option does not confer upon the Holder any right to vote or to consent to or
      receive notice as a stockholder of the Company, as such, in respect of any
      matters whatsoever, or any other rights or liabilities as a stockholder, prior
      to the exercise of this Option. If this Option is exercised only in part, the
      Holder shall have no such rights or liabilities with respect to any unexercised
      portion of this Option.

    


    
      
        
        

      

      
        -
          3
          -

        
          

        

      

      
        
        

      

    

     

    8)    Notices.
      No
      notice or other communi-cation under this Option shall be effective unless,
      but
      any notice or other communication shall be effective and shall be deemed to
      have
      been given if, the same is in writing and is mailed by first-class mail, postage
      prepaid, addressed to:

     

    
      	 	If to the Holder:	
              DEKK-Tec,
                Inc.

              c/o
                Lee Roy Morgan

              725
                Topaz Street

              New
                Orleans, LA 70124-3623

            
	 	 	 
	 	If to the Company:	
              ZIOPHARM,
                Inc.

              1180
                Avenue of the Americas, 19th
                Floor

              New
                York, NY 10036

              Attn:
                Chief Executive Officer

            


    

     

    9)    Investment
      Intent.

    


    (a)    The
      Holder represents by accepting this Option that it understands that this Option
      and any securities obtainable upon exercise of this Option have not been
      registered for sale under Federal or state securities laws and are being offered
      and sold to the Holder pursuant to one or more exemptions from the registration
      requirements of such securities laws. The Holder is an “accredited investor”
within the meaning of Regulation D under the Act. In the absence of an effective
      registration of such securities or an exemption from such registration any
      certificates for such securities shall bear a legend substantially similar
      to
      the legend set forth on the first page of this Option. The Holder understands
      that it must bear the economic risk of its investment in this Option and any
      securities obtainable upon exercise of this Option for an indefinite period
      of
      time, as this Option and such securities have not been registered under Federal
      or state securities laws and therefore cannot be sold unless subsequently
      registered under such laws, unless as exemption from such registration is
      available.

    


    (b)    The
      Holder, by its acceptance of this Option, represents to the Company that it
      is
      acquiring this Option and will acquire any securities obtainable upon exercise
      of this Option for its own account for investment and not with a view to, or
      for
      sale in connection with, any distribution of such securities in violation of
      the
      Act. The Holder agrees that this Option and any such securities will not be
      sold
      or otherwise transferred unless (i) a registration statement with respect to
      such transfer is effective under the Act and any applicable state securities
      laws or (ii) such sale or transfer is made pursuant to one or more exemptions
      from the Act.

    


    
      
        
        

      

      
        -
          4
          -

        
          

        

      

      
        
        

      

    

     

    10)    Headings.
      The
      headings of this Option have been inserted as a matter of convenience and shall
      not affect the construction of this Option.

    


    11)    Applicable
      Law.
      This
      Option shall be governed by and construed in accordance with the laws of the
      State of New York, without regard to principles of conflicts of law. The parties
      agree to settle any disputes through binding arbitration in the city, county
      and
      State of New York.

    


    The
      Company has caused this Option to be signed by its President and Chief Operating
      Officer to be effective as of October 15, 2004.

    


    
      	 	 	 
	 	
              ZIOPHARM,
                INC.

            
	 
 	 
 	 
 
	 	By:  	/s/ Richard
              E. Bagley
	 	
              

            
	 	Name:  	Richard E. Bagley
	 	Title 	President
&
              Chief Operating Officer


    

     

    
      
        
        

      

      
        -
          5
          -

        
          

        

      

      
        
        

      

    

     

    SUBSCRIPTION

    


    


    The
      undersigned, ___________________, pursuant to the provisions of the foregoing
      Option, hereby elects to exercise the foregoing Option to the extent of
      purchasing ____________________ shares of Common Stock under such Option and
      hereby makes payment of $___________ by certified or official bank check in
      payment of the exercise price for such Option .

    


    The
      undersigned hereby represents and warrants to the Company that the undersigned
      is acquiring the shares of the Company's Common Stock pursuant to exercise
      of
      the foregoing Option for investment purposes only. The undersigned hereby
      further acknowledges that the undersigned understands that such shares (a)
      have
      not been registered under the Securities Act of 1933, as amended (the
“Act”),
      and
      are being issued to the undersigned by the Company in reliance upon the
      foregoing representation and warranty and (b) may not be resold except in
      accordance with the requirements of the Act, including Rule 144 under the Act,
      if applicable. The undersigned further consents to the placing of a legend
      on
      the certificates for the shares being purchased to the foregoing
      effect.

    


    


    
      	Date: ___________________________   	Signature:   ________________________________________________
	 	 
	 	Address:    ________________________________________________


    

          

    
      
        
        

      

      
        -
          6
          -

        
          

        

      

      
        
        

      

    

     

    ASSIGNMENT

    


    


    FOR
      VALUE
      RECEIVED, _______________ hereby sells, assigns and transfers unto
      ____________________ the foregoing Option and all rights evidenced by such
      Option, and does irrevocably constitute and appoint _____________________,
      attorney, to transfer such Option on the books of ZIOPHARM, Inc.

    


    
      


      
        
          	Date: ___________________________   	Signature:   ________________________________________________
	 	 
	 	Address:    ________________________________________________


        



      
        
          
          

        

        
          -
            7
            -

          
            

          

        

        
          
          

        

      

    

        

    PARTIAL
      ASSIGNMENT

    


    


    FOR
      VALUE
      RECEIVED, _______________ hereby assigns and transfers unto ____________________
      the right to purchase _______ shares of the Common Stock of ZIOPHARM, Inc.
      covered by the foregoing Option, and a proportionate part of such Option and
      the
      rights evidenced by such Option, and does irrevocably constitute and appoint
      ____________________, attorney, to transfer that part of such Option on the
      books of ZIOPHARM, Inc.

    


    
      


      
        	Date: ___________________________   	Signature:   ________________________________________________
	 	 
	 	Address:    ________________________________________________


      

    

    


    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    


    ZIOPHARM
      Oncology, Inc.

    


    Addendum
      Dated September 14, 2005

    to

    Option
      for the Purchase of Shares of Common Stock

    dated
      October 15, 2004

    


    


    Pursuant
      to an Agreement and Plan of Merger dated August 3, 2005, on September 13, 2005,
      a wholly-owned subsidiary of EasyWeb, Inc. merged with and into ZIOPHARM, Inc.
      (“ZIOPHARM”)
      with
      ZIOPHARM remaining as the surviving corporation and a wholly-owned subsidiary
      of
      EasyWeb, Inc. (the “Merger”).
      On
      September 14, 2005, ZIOPHARM was merged with and into EasyWeb, Inc. and the
      combined corporation changed its name to ZIOPHARM Oncology, Inc. (“ZIOPHARM
      Oncology”).
      In
      accordance with the terms of the Merger, each outstanding option, warrant or
      other right to purchase capital stock of ZIOPHARM was automatically converted
      into an option, warrant or other right to purchase approximately 0.500974 shares
      of common stock of ZIOPHARM Oncology, $.001 par value per share (“ZIOPHARM
      Oncology Common Stock”),
      rounded down to the nearest whole share, for each share of ZIOPHARM capital
      stock subject to such option, warrant or other right immediately prior to the
      Merger. As a result, this option, warrant or other right was adjusted such
      that
      the holder is entitled to purchase shares of ZIOPHARM Oncology Common Stock
      in
      the amounts, and at the per share exercise price, set forth below: 

    


    


    
      	
              Number
                of Shares:          
                   27,616         
                 

               

              Exercise
                Price:               
                $0.02/share       

            	 
	 	 
	 	 


    

    


    
      	
              Vesting
                Schedule:

            	 
	 	 
	
              No.
                of Shares

            	
              Vesting
                Date

            
	 	 
	
              6,904

            	
              October
                15, 2004

            
	
              6,904

            	
              Upon
                the dosing of the first patient in the first Phase III clinical trial
                of
                Licensed Product in the United States under a Company or Company
                sublicense sponsored IND

            
	
              13,808

            	
              Upon
                the final approval by the FDA of the first NDA submitted by the Company
                or
                its sublicensee for a Licensed
                Product